Financials' strength keeps ISEQ up
Warner Chilcott's FDA approval for menopause symptom drug Femtrace has not helped the company share price this morning, after it fell by nine cent to €8.87.
The company expects to launch Femtrace tablets in the first quarter of 2005.





